Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: New therapeutic standard?

Internal and Emergency Medicine

Volumn 8, Issue 8, 2013, Pages 673-680

  Rubboli, Andrea ^a   Oldgren, Jonas ^b   Marìn, Francisco ^c   Lip, Gregory ^d  

^a MAGGIORE HOSPITAL   (Italy)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acute coronary syndromes; Apixaban; Dabigatran; Darexaban; Oral anticoagulation; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG COMBINATION; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG COMBINATION; HUMAN; ORAL DRUG ADMINISTRATION; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; TICLOPIDINE;

EID: 84888265498     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-1008-9     Document Type: Review

References (27)

1. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W (2000) Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21: 1406-1432.
2. van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, ESC Committee for Practice Guidelines (CPG) (2008) ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909-2945.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsèn M, PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
5. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103: 841-848.
6. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90: 61-68.
7. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143: 241-250.
8. Agnelli G, Becattini C (2009) New oral anticoagulants: just a new therapeutic option or a real breakthrough? Intern Emerg Med 4: 455-457.
9. Coccheri S, Orlando D (2013) New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. Intern Emerg Med 8: 115-122.
10. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nyström P, Bylock A, ESTEEM Investigators (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362: 789-797.
11. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, van de Werf F, Wallentin L, RE-DEEM Investigators (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32: 2781-2789.
12. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. N Engl J Med 119: 2877-2885.
13. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS TIMI 46): a randomized, double-blind, phase II trial. Lancet 374: 29-38.
14. Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB, RUBY-1 Investigators (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM 150) following acute coronary syndrome. Eur Heart J 32: 2541-2554.
15. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L, APPRAISE-2 Investigators (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365: 699-708.
16. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2-TIMI 51 Investigators (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366: 9-19.
17. Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34: 1670-1680.
18. Rubboli A (2012) The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. Intern Emerg Med 7: 299-304.
19. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators (2010) Rivaroxaban versus warfarin in valvular atrial fibrillation. N Engl J Med 376: 975-983.
21. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 33: 2569-2619.
22. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 32: 2999-3054.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators (2008) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
24. Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, Gibson CM (2013) Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS-ACS 2-TIMI 51). Am J Cardiol. doi: S0002-9149(13)00984-3.
25. Rivaroxaban approved for ACS secondary prevention in Europe. www. theheart. org/article/1543353. do. 24 May 2013.
26. Wallentin L, Becker RC, James SK, Harrington RA (2011) The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 105: 760-762.
27. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM, WOEST study investigators (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381: 1107-1115.